RCKTNasdaq

Rocket Pharmaceuticals Inc.

Healthcare·Rare Disease·Phase 2·Cranbury, NJ, United States
Rare DiseaseGene TherapyCardiovascularHematology

Rocket Pharmaceuticals Inc. (RCKT): 25 pipeline candidates · ~9 mo cash runway · 13 clinical trials. Updated within the last hour.

5.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway2.6

9.4 months

Financial Health9.4

D/E 0.20 · 3% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth10.0

25 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.0

1 buy · 14 sells (180d)

A transparent, data-derived signal for Rocket Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$300.3M

Cash

$51.0M

Quarterly Burn

$45.4M

Runway

9.4 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2027
Today~10 mo out
Catalyst within runway

Pipeline (25 candidates)

Showing 10 of 25 candidates. Sign up for full pipeline.

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

196

Total value held

$350.5M

HolderSharesValue
rtw investments, lp17,687,772$63.3M
blackrock, inc.7,834,795$28.0M
vanguard capital management llc7,551,472$27.0M
citigroup inc5,107,708$18.3M
vanguard portfolio management llc4,690,215$16.8M
state street corp4,485,989$16.1M
maverick capital ltd3,567,372$12.8M
newtyn management, llc3,165,900$11.3M
millennium management llc3,118,124$11.2M
aqr capital management llc3,069,930$11.0M

Showing top 10 of 196 institutional holders of Rocket Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

13 clinical trials·CEO: Dr. Gaurav D. Shah M.D.

Frequently asked questions

How many drug candidates are in Rocket Pharmaceuticals Inc.'s pipeline?

Rocket Pharmaceuticals Inc. (RCKT) has 25 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Rocket Pharmaceuticals Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Rocket Pharmaceuticals Inc. has approximately 9.4 months of cash runway.

What is Rocket Pharmaceuticals Inc.'s market capitalization?

Rocket Pharmaceuticals Inc.'s market capitalization is approximately $300.3M.

Who is the CEO of Rocket Pharmaceuticals Inc.?

Dr. Gaurav D. Shah M.D. is the chief executive officer of Rocket Pharmaceuticals Inc. (RCKT).

Get the full picture on Rocket Pharmaceuticals Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.